AIMC Topic: Janus Kinase 2

Clear Filters Showing 1 to 10 of 10 articles

Mechanism of triptolide in the treatment of gastric cancer with diabetes through JAK2/STAT3 pathway.

European journal of pharmacology
Univariate and multivariate Cox analyses revealed a correlation between diabetes and the prognosis of gastric cancer patients (p < 0.05). Using bioinformatics, Serine/threonine-protein kinase pim-1 (PIM1) was identified as the core target gene of tri...

Tanshinone IIA ameliorates pancreatic injury in type 2 diabetic mice by modulating inflammation and endoplasmic reticulum stress via the IL-6/JAK2/STAT3 pathway.

Functional & integrative genomics
Type 2 diabetes mellitus (T2DM) is a severe metabolic disorder in which pancreatic injury plays a pivotal role in disease progression. Tanshinone IIA (TanIIA), a bioactive compound extracted from Salvia miltiorrhiza, has shown therapeutic potential i...

Development of machine learning models based on molecular fingerprints for selection of small molecule inhibitors against JAK2 protein.

Journal of computational chemistry
Janus kinase 2 (JAK2) is emerging as a potential therapeutic target for many inflammatory diseases such as myeloproliferative disorders (MPD), cancer and rheumatoid arthritis (RA). In this study, we have collected experimental data of JAK2 protein co...

Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors.

Journal of chemical information and modeling
Developing Janus kinase 2 (JAK2) inhibitors has become a significant focus for small-molecule drug discovery programs in recent years because the inhibition of JAK2 may be an effective approach for the treatment of myeloproliferative neoplasm. Here, ...

[Coexistence of mycosis fungoides and essential thrombocythemia with JAK2V617F].

Revista medica del Instituto Mexicano del Seguro Social
BACKGROUND: The coexistence of myeloproliferative neoplasms (MPNs), specifically essential thrombocythemia and lymphoproliferative neoplasms, are a very rare finding with a frequency < 1%.

Deep reinforcement learning for de novo drug design.

Science advances
We have devised and implemented a novel computational strategy for de novo design of molecules with desired properties termed ReLeaSE (Reinforcement Learning for Structural Evolution). On the basis of deep and reinforcement learning (RL) approaches, ...

Machine Learning Classifier Using Blood Count Parameters and Erythropoietin to Predict JAK2 Mutations in Patients With Erythrocytosis.

Archives of pathology & laboratory medicine
CONTEXT.—: Differentiating polycythemia vera from other causes of erythrocytosis is a diagnostic challenge. Although most patients with polycythemia vera have Janus kinase 2 (JAK2) mutations, extensive testing is impractical because this is an uncomm...

Can polycythaemia vera disease be predicted from haematologic parameters? A machine learning-based study.

Journal of clinical pathology
AIMS: The aim of this research is to diagnose polycythaemia vera (PV) disease using different machine learning (ML) algorithms with complete blood count (CBC) parameters before further investigations such as Janus kinase 2 (), erythropoietin (EPO) an...

Leukaemia Stem Cells and Their Normal Stem Cell Counterparts Are Morphologically Distinguishable by Artificial Intelligence.

Journal of cellular and molecular medicine
Leukaemia stem cells (LSCs) are a rare population among the bulk of leukaemia cells and are responsible for disease initiation, progression/relapse and insensitivity to therapies in numerous haematologic malignancies. Identification of LSCs and monit...

JAKCalc: A machine-learning approach to rationalized JAK2 testing in patients with elevated hemoglobin levels.

Medicine
The demand for Janus Kinase-2 (JAK2) testing has been disproportionate to the low yield of positive results, which highlights the need for more discerning test strategies. The aim of this study is to introduce an artificial intelligence application a...